TRPM8 contributes to sex dimorphism by promoting recovery of normal sensitivity in a mouse model of chronic migraine

Received: 8 October 2021
Accepted: 30 September 2022
Published online: 22 October 2022

TRPA1 and TRPM8 are transient receptor potential channels expressed in trigeminal neurons that are related to pathophysiology in migraine models. Here we use a mouse model of nitroglycerine-induced chronic migraine that displays a sexually dimorphic phenotype, characterized by mechanical hypersensitivity that develops in males and females, and is persistent up to day 20 in female mice, but disappears by day 18 in male mice. TRPA1 is required for development of hypersensitivity in males and females, whereas TRPM8 contributes to the faster recovery from hypersensitivity in males. TRPM8-mediated antinociception effects required the presence of endogenous testosterone in males. Administration of exogenous testosterone to females and orchidectomized males led to recovery from hypersensitivity. Calcium imaging and electrophysiological recordings in in vitro systems confirmed testosterone activity on murine and human TRPM8, independent of androgen receptor expression. Our findings suggest a protective function of TRPM8 in shortening the time frame of hypersensitivity in a mouse model of migraine.

Chronic migraine is a highly prevalent and recurrent headache affliction particularly severe in women. While considerable advances have been made in the understanding of the disease, the mechanisms underlying the sex dimorphism of chronic migraine remain largely unknown. A migraine model with high predictive validity is the sensory sensitization induced by nitroglycerin (NTG). Acute NTG treatments lead to a delayed hypersensitivity to mechanical stimulation that lasts hours in humans and rodents. Furthermore, repeated NTG exposure causes a chronic hypersensitivity that lasts several weeks in murine models. This chronic hypersensitivity is characterized by generalized cutaneous sensitization, which has also been described as a reliable predictor of migraine chronicity in humans that is found more prevalently in women.

Multiple migraine triggers including NTG have demonstrated a crucial involvement of transient receptor potential ankyrin 1 (TRPA1) in rodent models of acute migraine. In these acute models, NTG acts as a donor of nitric oxide triggering a TRPA1-mediated neuronal activity that promotes nociceptive hypersensitivity. Indeed, TRPA1 is expressed in primary afferent neurons innervating the meninges where its activation favors the release of α-calcitonin gene-related peptide (αCGRP), a neuropeptide that plays a pivotal role in migraine development. Thus, TRPA1 antagonists reduce meningeal inflammation and hypernociception in basic pain models and αCGRP inhibition constitutes an effective strategy for migraine treatment in humans. Although recent reports have described higher contribution of αCGRP in females, the involvement of TRPA1 in males and females has not been yet studied in preclinical models of chronic migraine.

1 Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, Elche, Spain.
2 These authors contributed equally: David Alarcón-Alarcón, David Cabañero.
3 These authors jointly supervised this work: Asia Fernández-Carvajal, Antonio Ferrer-Montiel.
4 E-mail: dcabanero@umh.es; asia.fernandez@umh.es; aferrer@umh.es
An additional TRP channel tightly associated with the expression of chronic migraine in humans is the transient receptor potential melastatin 8 (TRPM8). Several single-nucleotide polymorphisms affecting TRPM8 have been linked to chronic migraine and alldynia. Concurrently, TRPM8 agonists such as menthol have been used medicinally for the alleviation of migraine-related pain. TRPM8 is a cation channel expressed in primary afferent neurons, known for being the menthol receptor and the principal detector of environmental cold. As such, TRPM8 activity shows modulatory effects on thermal and mechanical hypersensitivity in preclinical models of pain. However, its presence in internal structures kept at euthermic temperature and its recent description in central brain areas suggest additional functions of this protein that may go beyond cold perception. In this line, TRPM8 was previously described as a testosterone receptor in cellular models. While high testosterone levels have been associated with decreased nociceptive sensitivity in mice and humans, it is unknown whether testosterone-TRPM8 interactions could have functional relevance in nociception.

Here we implemented a murine model of chronic migraine that displays a sexual dimorphism characterized by enhanced nociceptive sensitivity of females as described in humans. The aim of the study was to investigate the involvement of TRPA1 and TRPM8 in this sexually dimorphic behavior. To address this, mechanical sensitivity was assessed in mice of both sexes chronically exposed to NTG and the participation of TRPA1 and TRPM8 was evaluated through genetic and pharmacological approaches. To dissect the functional and molecular consequences of TRPA1 and TRPM8 activities, murine cultures of trigeminal neurons and transfected cell lines expressing murine and human receptors were evaluated through calcium imaging. After finding a male-specific function of TRPM8, the role of testosterone-TRPM8 interactions and the effects of exogenous TRPM8 stimulation were elucidated in vitro and in vivo models of acute and chronic pain. Molecular docking in human ligand-receptor models may provide further insight on testosterone activity through TRPM8 and the effects of this interaction were corroborated through electrophysiological recordings that show independency of androgen receptor expression. Collectively, our data suggest that testosterone, through its interaction with TRPM8, drives sexual dimorphism in the model of chronic migraine and likely in other pain-related behaviors.

**Results**

**Repeated NTG treatment induces a persistent mechanical hypersensitivity that remains up to 20 days in female mice but disappears in male mice**

We implemented in our laboratory a modification of a previous model of chronic migraine induced by repeated NTG treatment. NTG (10 mg/kg) or vehicle (5% dextrose and 0.105% propylene glycol in water) were administered intraperitoneally once every 2 days to male and female mice, and mechanical sensitivity was assessed before and after each treatment and for 12 additional days after the end of the repeated administrations (Fig. 1a). Two hours after each NTG treatment, acute hypersensitivity was observed in male and female mice, whereas the vehicle did not induce nociceptive sensitization (Fig. 1b, left panel, p < 0.001 treatment effect). Mechanical sensitivity assessed before NTG injections and after the end of the repeated treatment (up to 20 days after beginning of the treatments, right panel of Fig. 1b) showed a long-lasting hypersensitivity in male mice (days 2–16, p < 0.05 vs. baseline and vehicle, Fig. 1b) that returned to baseline values 8 days after the last NTG injection (day 18, Fig. 1b, nonsignificant vs. baseline or vs. vehicle). In contrast, female mice presented a persistent cutaneous hypernociception that was significant until the end of the experimental procedure (p < 0.05 vs. baseline, vs. vehicle, Fig. 1b). Thus, data obtained in this observation period indicate a sexual dimorphism as males can fully recover from NTG sensitization, while females improve partially.

**Repeated NTG treatment induces long-lasting TRPA1-dependent hypersensitivity in female and male mice**

Migraine-related nociception produced by acute NTG treatment has been associated to TRPA1 activity in trigeminal ganglia of male mice. We investigated the possible participation of TRPA1 on the model of chronic migraine. Wild-type and TRPA1 knockout mice received NTG injections and mechanical sensitivity was assessed (Fig. 2a). As expected, wild-type mice showed acute hypersensitivity 2 h after each NTG injection. On the contrary, this sensitization was absent in TRPA1 knockout mice of both sexes (Fig. 2a, p < 0.001 genotype effect, left panel), in agreement with a previous study describing lack of acute NTG sensitization in TRPA1 knockout males. TRPA1 deletion also prevented the development of chronic hypersensitivity in males and females (Fig. 2a, right panel).

To understand the role of TRPA1 in mediating NTG-induced sensitization in mice, we assessed TRPA1 mRNA expression and intracellular calcium imaging in trigeminal ganglia of male and female mice chronically exposed to NTG (Fig. 2b, c). Samples from NTG-treated wild-type animals showed an increased TRPA1 mRNA expression regardless of the sex (Fig. 2b, p < 0.001 vs. vehicle). In parallel, trigeminal neuronal cultures of male and female mice revealed calcium transients in response to the TRPA1 agonist allyl isothiocyanate (AITC) at 70 µM (Fig. 2c). These responses were of similar magnitude in samples of both sexes and had higher amplification in neurons of mice chronically exposed to NTG (p < 0.01 vs. vehicle, Fig. 2d). These results obtained with non-ratiometric calcium imaging were obtained by normalization of AITC-induced transients to 40 mM KCl responses which were similar in vehicle and NTG-treated mice. The neuronal population responding to AITC was composed of small to medium size neurons (100–700 µm², Supplementary Fig. 2a). This increased TRPA1 responsiveness was also characterized by a higher percentage of cells showing significant activity (percentage of KCl-sensitive cells, p < 0.001 vs. vehicle, Supplementary Fig. 2b), and the size of these responses was proportional to the percentage of sensitive cells (Supplementary Fig. 2c). Thus, the trigeminal cultures revealed small to medium size neurons with increased TRPA1 activity after chronic NTG treatment, regardless of the sex.

To further investigate TRPA1 involvement on NTG sensitization, trigeminal neurons of naïve wild-type and TRPA1 knockout mice were cultured to assess calcium responses. These neurons were challenged with 100 µM NTG followed by 70 µM AITC (Fig. 2e). A 15.7 ± 3.2% of the cells responded to both stimuli in wild-type mice, while this percentage decreased drastically in TRPA1 knockouts (0.6 ± 0.3%, p < 0.001, Fig. 2f), revealing an essential participation of TRPA1 in calcium transients elicited by both NTG and AITC in mice. To assess the translatability of this NTG activity to human TRPA1, NTG was applied to human TRPA1-transfected HEK293 cells and IMR90 fibroblast cells natively expressing this receptor (Fig. 2g). Both cell types showed a dose-dependent relationship for NTG-evoked calcium influx, whereas control HEK293 cells did not respond. Thus, NTG activated both human and murine TRPA1 channels.

TRPA1-mediated trigeminal sensitization may involve the release of the vasodilator peptide αCGRP. This neuropeptide is an essential neurotransmitter for migraine neuroinflammation and pain. Hence, we next examined NTG-induced αCGRP release in cultured trigeminal neurons through αCGRP immunofluorescence. A treatment with DDO4107, an exocytosis inhibitor that interacts with the exocytosis-related protein SNAP-25, was used to investigate vesicular release. Control neurons exposed to NTG vehicle showed stronger αCGRP immunoreactivity than NTG-treated neurons (Fig. 2h, i, p < 0.001) suggesting vesicular αCGRP release after NTG. In contrast, neurons pre-treated with DDO4107 showed significantly higher αCGRP...
We next analyzed its expression in trigeminal ganglia of male and female mice. Experiments to test the antinociceptive efficacy of WS12 in wild-type female mice sensitized after chronic NTG. This finding revealed a protective function of TRPM8 in males subjected to NTG-mediated chronic sensitization and signaled a potential role of this channel in sex dimorphism in the model of chronic migraine.

To investigate the involvement of TRPM8 in sex dimorphism, we next analyzed its expression in trigeminal ganglia of male and female wild-type mice chronically exposed to NTG. TRPM8 mRNA values were similar regardless of treatment and sex (Fig. 3b). Functionally, perfusion with the selective and potent TRPM8 agonist WS12 (500 nM) elicited calcium transients of similar amplitude in both sexes, after chronic vehicle or NTG (Fig. 3c, d). WS12 activated 8 ± 2.1% of the cultured neurons (Supplementary Fig. 3a), which were small size cells (50–200 μm², Supplementary Fig. 3b). This percentage was similar in samples of vehicle and females, whereas female or male mice treated with vehicle show normal sensitivity. Data are mean ± S.E.M. **p < 0.01, ***p < 0.001 vs. vehicle.

Fig. 1 | Chronic nitroglycerin administration induces generalized long-lasting mechanical hypersensitivity in male and female mice. A Model of chronic migraine induced by five intraperitoneal injections of 10 mg/kg nitroglycerin or its vehicle administered every other day (days 0, 2, 4, 6 and 8). Hind paw mechanical sensitivity was assessed with von Frey filaments 2 h after nitroglycerin administration (blue lines), before nitroglycerin injections and after the end of the treatments on days 10, 12, 14, 16, 18 and 20 (black lines). Tissue samples were obtained at the end. B Left panels. Nitroglycerin (red) induces similar acute hypersensitivity in males and females, whereas the vehicle (black, 5% dextrose, 0.105% propylene glycol) did not induce nociceptive sensitization. B Right panels. Chronic administration of nitroglycerin induces a long-lasting hypersensitivity that is persistent exclusively in females, whereas female or male mice treated with vehicle show normal sensitivity. Data are mean ± S.E.M. **p < 0.01, ***p < 0.001 vs. vehicle. Source data provided in the Source Data file, statistical results in Supplementary Table 1.

TRPM8 activity determines the recovery of normal sensitivity in male mice exposed to the model of chronic migraine

TRPM8 is a thermoTRP channel that has been signaled in the pathophysiology of chronic migraine. Thus, we next investigated the involvement of TRPM8 in NTG chronic sensitization. For this purpose, male and female wild-type and TRPM8 knockout mice were exposed to the chronic NTG treatment (Fig. 3a). Wild-type males presented the expected sensitization (Fig. 3a, p < 0.01 vs. Baseline on days 8 and 15) that was resolved by the end of the experimental procedure (day 20, Fig. 3a). Noteworthy, TRPM8 knockout males maintained a persistent sensitization that was significant until the last day of measurements, akin to the persistent sensitization observed in females (p < 0.01 vs. Baseline and wild-type, Right panel of Fig. 3a). This finding revealed a protective function of TRPM8 in males subjected to NTG-mediated chronic sensitization and signaled a potential role of this channel in sex dimorphism in the model of chronic migraine.

To investigate the involvement of TRPM8 in sex dimorphism, we next analyzed its expression in trigeminal ganglia of male and female wild-type mice chronically exposed to NTG. TRPM8 mRNA values were similar regardless of treatment and sex (Fig. 3b). Functionally, perfusion with the selective and potent TRPM8 agonist WS12 (500 nM) elicited calcium transients of similar amplitude in both sexes, after chronic vehicle or NTG (Fig. 3c, d). WS12 activated 8 ± 2.1% of the cultured neurons (Supplementary Fig. 3a), which were small size cells (50–200 μm², Supplementary Fig. 3b). This percentage was similar in samples of vehicle and NTG-treated mice. Hence, trigeminal cultures showed that TRPM8 activity and expression were similar between sexes and after the NTG treatment.

Given this similar functionality, we conducted additional experiments to test the antinociceptive efficacy of WS12 in wild-type female mice sensitized after chronic NTG. On day 20, females received WS12 or its vehicle. The observed responses were highly variable and nonsignificant results were found after 10 mg/kg WS12 (i.p.), a dose with reported antinociceptive efficacy in male mice (Fig. 3e). In a separate experiment, we tested the effect of lower (5 mg/kg, Supplementary Fig. 4a) and higher doses of WS12 (20 mg/kg, Supplementary Fig. 4b) in wild-type and TRPM8 knockout females. Both the highest dose (Supplementary Fig. 4b, p = 0.053 vs. vehicle), and the lowest dose were ineffective. WS12 showed efficacy when administered in a vehicle containing 5% ethanol and 43% cyclodextrin, however possible antinociceptive effects of this vehicle were detected (Supplementary Fig. 4c). To further characterize the...
in vivo activity of WS12 in females, we decided to examine the antinociceptive effect of TRPM8 activity on the formalin pain model, another TRPA1-dependent pain model. As illustrated in Fig. 3f, WS12 induced significant antinociception in the acute phase, whereas the late phase was unaltered, revealing a short-lasting effect of this compound.

To further investigate the function of TRPM8 in wild-type males, mice previously exposed to NTG that had recovered their baseline sensitivity were exposed to increasing doses of the TRPM8 blocker AMTB (Fig. 3g). This compound precipitated a significant re-sensitization when administered at 10 or 15 mg/kg (p < 0.05 vs. vehicle, Fig. 3g) in this model. Interestingly, similar results were obtained in male mice previously subjected to the formalin test. To corroborate the existence of a TRPM8-dependent tone in males providing relief after TRPA1-induced nociception, male mice were treated with AMTB after the extinction of formalin-induced nocifensive activity. These mice showed a significant reinstatement of licking behavior evident 30 min after administration of the compound (p < 0.05 vs. vehicle, Fig. 3h). Altogether, these results suggest the presence of endogenous TRPM8 activity with antinociceptive function in male mice.
Testosterone activates TRPM8 to resolve mechanical sensitization in mice exposed to the model of chronic migraine

Testosterone has been suggested as an endogenous TRPM8 agonist\(^\text{28}\) and shows antinociceptive functions in mice\(^\text{7}\). We hypothesized that this endogenous androgen could have a protective function in the mouse model of chronic migraine. To address this question, mice were first subjected to a sham surgery or to an orchidectomy to deplete gonadal testosterone. Once their nociceptive sensitivity was restored the animals received the NTG treatment (Fig. 4a). Acute NTG produced similar hypernociception in sham and orchidectomized animals (Fig. 4a, left panel, \(p < 0.001\) vs. vehicle). In contrast, the repeated NTG evidenced a persistent chronic sensitization selectively expressed in orchidectomized animals (Fig. 4a, right panel, \(p < 0.01\) vs. sham), indicating possible protective role of testosterone.

To investigate whether testosterone could have TRPM8-mediated antinociceptive effects in males, wild-type and TRPM8 knockout males were orchidectomized and received subcutaneous osmotic pumps filled with testosterone or its vehicle (cyclodextrin 45% in water). Afterwards, all mice were chronically treated with NTG, and their mechanical sensitivity was assessed. Testosterone induced complete recovery of mechanical thresholds in wild-type mice (Fig. 4b, right panel, day 20, \(p < 0.001\) vs. Vehicle wild-type, nonsignificant vs. baseline), while vehicle-treated animals remained sensitized by the end of the experiment (Fig. 4b, right panel, \(p < 0.001\) vs. baseline on day 20). In contrast, TRPM8 knockout mice lacked this restorative effect of testosterone (Fig. 4b, right panel, day 20, \(p < 0.001\) vs. wild-type, \(p < 0.001\) vs. baseline), although an antinociceptive effect independent of TRPM8 activity was also evidenced in knockouts (Fig. 4b, right panel, day 20, \(p < 0.05\) vs. vehicle TRPM8 knockout). To further clarify the involvement TRPM8 in the protective effect of testosterone, AMTβ was administrated to all mice after the nociceptive measurement on day 20 (Fig. 4c). A significant drop in the mechanical thresholds was selectively observed in wild-type mice treated with testosterone (Fig. 4c, \(p < 0.01\) vs. values before AMTβ), whereas mice receiving vehicle and knockouts showed unaltered mechanosensitivity. These results revealed significant testosterone-TRPM8 antinociception in males.

Next, to determine whether testosterone could have rapid antinociceptive effects we treated NTG-exposed wild-type and TRPM8 knockout females with a single subcutaneous administration of 1 mg/kg testosterone or its vehicle (2.5% DMSO in corn oil, Fig. 4d). A significant testosterone-induced antinociception was observed selectively in wild-type mice (\(p < 0.05\) vs. pre-treatment values, \(p < 0.05\) vs. testosterone-treated TRPM8 knockouts). Overall, the present behavioral results suggest nongenomic antinociceptive effects of testosterone through TRPM8.

We next investigated if testosterone activated TRPM8 channels in trigeminal cultures as a mechanism to account for the protective role of the androgen. Trigeminal cultures of wild-type mice showed calcium transients in response to 10 µM testosterone (Fig. 4e). Cells responding to testosterone also presented calcium transients in response to 500 nM WS12 (7.9 ± 0.8% of KCl-sensitive cells; Fig. 4f). These responses were abolished in neural cultures from TRPM8 knockout animals (Fig. 4e, right panel, \(p < 0.001\) vs. wild-type), revealing a testosterone activity through TRPM8 in trigeminal neurons. Previous studies described structural and functional differences between murine and human TRPM8\(^\text{29}\). To evaluate this possibility, we assessed testosterone activity on HEK293 cells constitutively expressing murine or human TRPM8, whereas control HEK293 cells lacked this response (Fig. 4f). Altogether, the present data reveal a testosterone activity on murine and human TRPM8.

Testosterone-induced current of human TRPM8 is independent of androgen receptor expression

Given the possible interaction of testosterone with TRPM8, we conducted patch-clamp whole-cell recordings to assess possible testosterone-induced currents on HEK293 cells heterologously expressing human TRPM8 (hTRPM8-HEK293). Current density (pA/pF) vs. voltage relationships in these cells (Fig. 5a) evidenced an increase in outward rectifying current after 10 s application of 10 µM testosterone. This testosterone-induced current was significantly different from the basal current (Fig. 5b, \(p < 0.05\)) and was completely blocked in the presence of 10 µM AMTβ, the specific TRPM8 blocker (Fig. 5b, \(p < 0.01\) vs. 10 µM testosterone). As testosterone’s primary mechanism of action is through binding to the androgen receptor (AR), an additional experiment was conducted knocking down the androgen receptor in hTRPM8-HEK293 cells. Thus, hTRPM8-HEK293 cells were transfected with small interfering RNA (siRNA) targeting the AR or with scrambled siRNA. In parallel, wild-type HEK293 cells lacking heterologous expression of TRPM8 were assayed (WT HEK293). hTRPM8-HEK293 cells transfected with either anti-AR siRNA or scrambled siRNA showed similar current density-voltage curves after 10 µM testosterone (Fig. 5c), whereas WT HEK293 cells did not display testosterone-induced currents (\(p < 0.01\) WT HEK293 vs. hTRPM8-HEK293, current fold increase at \(+80\text{ mV}\) Fig. 5d). To ensure the silencing of AR expression, western blot was performed in samples of hTRPM8-HEK293 and WT HEK293 cells cultured in parallel to the cells used for electrophysiological recordings (Fig. 5e). A disruption of AR expression was confirmed in hTRPM8-HEK293 cells treated with anti-AR siRNA, whereas hTRPM8-HEK293 cells treated with scrambled siRNA or WT HEK293 cells presented evident AR expression. In order to allow the comparison to an established TRPM8 agonist in the same setting, we conducted dose-response curves for testosterone and WS12 in untreated hTRPM8-HEK293 cells, obtaining EC50s of 7 µM for...
testosterone and 500 nM for WS12 (Supplementary Fig. 5a). The EC50 of WS12 was afterwards used to estimate the IC50 of the TRPM8 antagonist AMTB, which also binds to the menthol-binding site36 (Supplementary Fig. 5b). Subsequent application of AMTB IC50 (15 nM) shifted the testosterone dose-response curve to the right (Fig. 5f, EC50 = 34 pM), being compatible with competitive inhibition. Hence, testosterone-induced currents were selectively elicited in HEK293 cells heterologously expressing human TRPM8, were independent of AR expression and sensitive to the TRPM8 antagonist AMTB, substantiating an ionotropic action of the hormone28.

**Discussion**

The most salient contribution of our study is the discovery of the role of TRPM8 as an androgen-activated receptor that provides...
antinociception in a sex-dependent fashion. Specifically, TRPM8 activity favors recovery in a mouse model of NTG-induced chronic migraine that produces similar acute mechanosensitivity in males and females but persistent chronic hypersensitivity exclusively in females. Our results suggest that testosterone by activating TRPM8 channels drives a sexual dimorphism characterized by recovery of normal sensitivity in males. We propose that the lack of this protective mechanism in females leads to a persistent male-like chronic hypersensitivity.

Our model of chronic migraine mimics the sexual dimorphism observed in humans, characterized by stronger transitions to chronic sensitization in women and possible faster recovery in men. Previous studies also described higher female sensitivity in models of formalin-inflammtory pain and models of persistent pain such as stress-induced visceral hypersensitivity or muscle pain after repeated saline injections and forced activity. We considered the direct assessment of trigeminal sensitization in the head, however the repeated restraint stress required for this type of assessment could have been an additional factor in promoting sexual dimorphism. Overall, these findings suggest that the exposure to repeated noxious insults such as ongoing inflammation and stress-related stimuli favor the perpetuation of painful responses in females, whereas males show faster recovery and are able of reinstating their normal sensitivity.

Our model of chronic migraine, NTG provokes mechanical hypersensitivity by signaling through the TRPA1 channel, although this receptor is not involved in the sex dimorphism observed. Indeed, repeated NTG exposure induced similar TRPA1 mRNA overexpression in trigeminal ganglia of male and female mice. Increased expression translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of male and female mice. Increased expression of TRPM8 mRNA is translated into exacerbated TRPA1 activity and trigeminal cultures of males and females chronically exposed to NTG presented stronger TRPA1 activity in response to the specific agonist aITC. In line with our results, previous research described TRPA1-specific neuronal responses after acute NTG, and male rodents exposed to NTG were sensitive to TRPA1 antagonism. Our findings reveal an essential participation of TRPA1 for the development of chronic NTG hypersensitivity in male and female mice, in agreement with studies showing TRPA1 involvement in persistent nociceptive sensitizations.

The NTG-TRPA1 mechanism involved in promoting the mechanical hypersensitivity relies on the release of aCGRP from trigeminal neurons, in agreement with the critical role of this neuropeptide in the aetiology of chronic migraine. Our data further substantiate this tenet as sensitivity to the exocytosis inhibitor DD04107 revealed a mechanism involving large dense core vesicles and vesicular fusion protein SNAP-25. Notably, the data obtained with DD04107 suggest a potential efficacy of this peptide for the treatment of chronic migraine through inhibition of aCGRP release, similar to botulinum neurotoxin. Accordingly, we propose antagonistic roles of TRPA1 and TRPM8 activities determined by the continuous exposure to exogenous and endogenous agonists. Namely, nitric oxide derived from the treatment with NTG elicits a hyperalgesic state via TRPA1 stimulation both in males and females, whereas testosterone exerts an antinociceptive role through interactions with TRPM8. Several mechanisms could underlie TRPM8-mediated antinociception. On the one hand, it has been proposed that TRPM8 activation produces silencing of CGRP release through interneuron recruitment in the spinal cord dorsal horn or via inhibitory metabolotropic glutamatergic receptors expressed in the central terminal of nociceptors. Thus, in the studied pain models TRPM8 activity may occlude signaling of TRPA1-expressing nociceptors and subsequent CGRP release. In addition, a participation of central brain areas cannot be excluded from our data, given the recent description of TRPM8 in supraspinal locations.

Notably, our results in TRPM8 knockout mice subjected to chronic NTG sensitization reveal a protective function of TRPM8. In line with our data, TRPM8 stimulation showed efficacy alleviating thermal hyperalgesia and nocifensive behaviors in models of headache-related pain. A protective function was similarly described in models of noxious heat or chemically-induced nociception such as the injection of capsaicin or the TRPA1 agonist acrolein. TRPM8 stimulation also provided alleviation of mechanical and cold sensitivity in models of chronic neuropathic pain. In accordance with these preclinical findings, TRPM8 agonists have been used medicaclly for alleviating a variety of pain conditions including headaches and migraine, although using these compounds is not a first-line treatment for this clinical condition. Our results may be in contrast with experiments recently published after the preprint of the present work in which TRPM8 is depicted as a trigger of nociceptive sensitization in the model of chronic migraine. While this work also stresses the relevance of TRPM8 for future investigations, we find experimental differences also involving NTG-induced sensitization that may explain the diverging results. Firstly, their exacerbated hypernociception may be associated with the combined use of NTG with propylene glycol as suggested by our data (Fig. 1 vs. Supplementary Fig. 1). Second, the NTG-induced hyperalgesia elicited in our model would have been overlooked in animals with a basal hypersensitive phenotype when compared to the mice used in our experimental conditions. Possible explanations to basal hyperreactivity include substrate differences or lack of habituation. Contradictory results were also published showing pro-allergenic effects of TRPM8 agonists on migraine, although the use of TRPM8 agonists with partial effect on TRPA1 such as icilin could have yielded misleading results. Similarly, we did not observe significant antinociception after administration of high WS12 doses in female mice treated with NTG. The absence of significant antinociception after WS12 could be associated to the potent and short-lasting effect of this compound, as suggested by the results obtained in the formalin test where significant effects lasted only 5 min in the acute phase. In agreement, calcium-dependent desensitization of TRPM8 is described
after application of the canonical TRPM8 agonists menthol, icilin or WS12\(^\text{53-55}\). In our von Frey experiments, reliable assessment of mechanosensitivity requires spaced and sequential application of von Frey filaments during periods of 15–30 min. Hence, mechanosensitivity could not be precisely assessed at that specific temporal resolution and a transient effect of WS12 could have been overlooked. In this line, short-lasting pain-relieving responses to menthol and its derivatives can be found clinically and were described elsewhere\(^\text{49}\). On the other hand, the poor hydrosolubility of WS12 required its dissolution in corn oil for systemic administration and the lack of a significant effect could also be related to an erratic absorption and distribution of the compound.

The protective role of TRPM8 was ratified by the AMTB-induced resensitization of males already recovered from the chronic NTG treatment. This protective TRPM8 activity was corroborated in males previously subjected to the classical formalin test and is compatible with a latent nociceptive sensitization masked by tonic TRPM8 activity. The development of latent nociceptive sensitizations or hyperalgesic priming has been related to the establishment of chronic pain conditions\(^\text{53-55}\) and an endogenous opioid tone has been associated with this tonic inhibition of nociception\(^\text{54}\). In this context, an interdependence between TRPM8 and the endogenous opioid system has been described, with TRPM8 knockout mice displaying reduced morphine analgesia and the antinociceptive effects of TRPM8 agonists...
Fig. 4 | Testosterone stimulates neuronal TRPM8 to promote recovery of normal mechanosensitivity after chronic nitroglycerin treatment. 

a Orchidectomized and sham mice display similar acute hypersensitivity after nitroglycerin (left panel), however only orchidectomized mice remain sensitized on day 21 (right). b Left, all orchidectomized mice show similar acute hypersensitivity after a first nitroglycerin dose, whereas after the last dose, orchidectomized TRPM8KO mice develop stronger sensitization. Right, mice receiving testosterone supplementation show inhibition of the long-lasting hypersensitivity induced after chronic nitroglycerin. This attenuation allows recovery of baseline sensitivity in wild-type mice, but not in TRPM8KO mice. c Testosterone-supplemented wild-type mice that recovered normosensitivity restate sensitization after AMTB on day 21. This response is absent in TRPM8 knockout d Sensitized wild-type females recover baseline sensitivity after acute testosterone treatment on day 21. e Cultured trigeminal neurons showing calcium transients after 10 pM testosterone also respond to 500 nM WS12 whereas TRPM8 knockouts are unresponsive. Right, 7% of neurons from wild-type trigeminal cultures show calcium transients after 10 pM testosterone and 500 nM WS12. This is abolished in TRPM8 knockouts. f 10 pM testosterone being sensitive to the opioid antagonist naloxone. Our results suggest the interest of investigating opioid-TRPM8 interactions for the promotion of antinociception.

Noteworthy, testosterone application provided rapid TRPM8-mediated antinociception in females. In line with this finding, orchidectomized males showed persistent sensitization after chronic NTG similar to females. Previous studies also described decreased ability of orchidectomized males in restoring normal mechanosensitivity after inflammatory or stress-related insults. These studies elucidated testosterone antinociceptive mechanisms including transformation to dihydrotestosterone and binding to androgen receptor, down-regulation of anti-opioid neurotransmitter Brain-derived Neurotrophic Factor (BDNF) or modulation of serotonin transporters. In our study, orchidectomized wild-type males exposed to testosterone recovered their normal sensitivity after cessation of the NTG treatment, and this effect was largely dependent on TRPM8. These data reveal a function of TRPM8 providing endogenous antinociception in males though testosterone stimulation. Male-specific alterations have been previously observed in TRPM8 knockouts, including delayed cold acclimation and lower bone mineral density, similar to females of either genotype that showed this same phenotype. Interestingly, these features are also tightly linked to the activity of sexual steroids. We observed rapid antinociceptive effects of testosterone in NTG-exposed females in a time frame in which acute testosterone anxiolytic effects are also found. In agreement, preclinical studies show antinociceptive efficacy of testosterone in male and female rodent models of acute and chronic pain. Consistently, clinical treatments with testosterone may provide pain alleviation, and testosterone levels of men and women are inversely proportional to pain perception including migraine pain. However, hormonal treatments are subject to tight regulation and have transcriptional effects and deleterious consequences that limit their use.

Our trigeminal cultures revealed TRPM8 calcium transients in response to picomolar concentrations of testosterone that were absent in cultures of TRPM8 knockouts. Whole cell patch-clamp recordings in HEK cells heterologously expressing human TRPM8 also revealed ion current effects at low picomolar testosterone concentrations (EC50 = 7 pM), in contrast to the lower potency of WS12 (EC50 = 500 nM) obtained in the same experimental conditions. These testosterone-induced currents were independent of androgen receptor expression and sensitive to the TRPM8 antagonist AMTB, as revealed by the 5-fold decrease in testosterone potency (EC50 increased from 7 to 34 pM) in the presence of 15 nM AMTB (IC50 of AMTB against the less potent WS12). Note that the high potency of testosterone evoking TRPM8 ionic currents, requires higher AMTB concentrations to abolish testosterone-induced TRPM8 responses. Indeed, 10 μM AMTB fully blocked testosterone-evoked ion currents.

In agreement with our data, other groups have revealed TRPM8-mediated currents after application of picomolar concentrations of testosterone to cancer cells, somatosensory neurons or planar lipid bilayers expressing TRPM8. Thus, testosterone induced rapid non-genomic effects on primary afferent neurons and other cell types through TRPM8. Similarly, other endogenous molecules such as oxytocin have shown agonistic effects over TRPV1 also at picomolar concentrations. While WS12 in the nanomolar range elicits stronger calcium transients than picomolar concentrations of testosterone, at the picomolar level TRPM8 agonists such as menthol, icilin or WS12 lack significant effects on intracellular calcium imaging. On the other hand, nanomolar concentrations of testosterone inhibited TRPM8 in HEK cells and neurons, suggesting possible inverted u-shaped dose-effect curves for this type of steroids. In agreement, picomolar concentrations of dihydrotestosterone induced pronounced over-expression of TRPM8 in cancer cells whereas higher concentrations had a reduced effect. Our calcium imaging, electrophysiological and behavioral results suggest an ionotropic effect of testosterone on TRPM8 channels and hint to the presence of a potential hormone binding site within the receptor structure. Docking simulations on a computational homology model of the human TRPM8 suggest the presence of a putative testosterone binding site in the receptor transmembrane domain with a theoretical binding energy and affinity consistent with the hormone potency (Supplementary Fig. 6a, b and Computational files.zip). Furthermore, this putative ligand-receptor complex model suggests binding of testosterone to the active pocket described for WS12 and menthol. Interestingly, female hormones such as estradiol or progesterone were also able to be positioned in this binding pocket (Supplementary Fig. 6c, d and Computational files.zip) although with lower binding energy estimates than testosterone. This agrees with the potency of estradiol and progesterone evoking TRPM8 ionic currents in planar lipid bilayers, as compared with testosterone. This computational docking model provides a testable hypothesis for future studies aimed to identify the molecular determinants of this putative binding site, either by structural and/or by structure-function studies. In this line TRPM3, another TRP channel described for WS12 and menthol also that responds to sexual hormones such as pregnenolone and progesterone, suggesting a dual role of these protein types as detectors of both exogenous and endogenous stimuli. Our data indicate a testosterone-TRPM8 interaction that could be helpful for the design of novel compounds mimicking this channel agonist activity without the unwanted effects of hormonal treatments.

In conclusion, a high sensitization level of females has been found in a model that reproduces the sexual dimorphism and the enhanced cutaneous sensitivity associated with chronic migraine in humans and especially in women. This type of chronic sensitization could be...
Fig. 5 | Testosterone increases outward current of heterologously expressed human TRPM8, independently of androgen receptor expression. a Current density (pA/pF) vs. voltage relationship evidences increase in outward rectifying current 10 pM testosterone in HEK293 cells expressing human TRPM8 (hTRPM8). 10 µM AMTB inhibits testosterone effect (n = 5 cells from two independent cultures). Each cell received a testosterone pulse followed by a pulse of AMTB with testosterone. 

b 10 pM testosterone increases basal TRPM8 current at +80 mV (n = 7 cells from two independent cultures; p < 0.017 vs. Basal current) and 10 µM AMTB reverses its effect (n = 5 cells from two cultures, p < 0.009 vs. 10 pM testosterone).

c hTRPM8 HEK 293 cells (hTRPM8 HEK) transfected with small interfering RNA (siRNA) against androgen receptor (AR) (n = 7 from two cultures) and control hTRPM8 HEK transfected with scrambled siRNA (n = 6 from two cultures) show similar testosterone-induced outward rectifying current. This current is absent in wild-type HEK293 cells (WT HEK, n = 6 from 1 culture) lacking TRPM8. d At +80 mV, testosterone-evoked current is similar in anti-AR siRNA or scrambled siRNA-transfected hTRPM8 HEK cells, and this current is absent in wild-type HEK (p < 0.046 vs. anti-AR siRNA, p < 0.005 vs. scrambled siRNA). e Western blot of AR (110 kDa) and β-tubulin loading control (50 kDa) shows disrupted AR expression in anti-AR siRNA-transfected hTRPM8 HEK cells. WT HEK and scrambled siRNA-transfected hTRPM8 HEK cells display similar AR expression. f 15 nM AMTB (IC50 for WS12 inhibition, Supplementary Fig. 5) shifts to the right the dose-response curve for testosterone-induced currents. EC50 for testosterone (7pM, 95% CI 6-8) increases in presence of AMTB (34 pM, 95% CI 16-61, n = 9 cells from three independent cultures for both dose-response curves).
aggravated after recurrent exposure to environmental factors involving TRPA1 stimulation such as pungent substances, oxidative stress or cyclic proinflammatory events51. The present data reveals that the difference between males and females is mainly due to an increased antinociception of males. This effect relies partly on TRPM8 activity in response to endogenous testosterone, an androgenic hormone that is present at much higher levels in male individuals. Hence, novel molecules mimicking testosterone activity on TRPM8 could lack the unwanted effects of hormonal treatments and may provide effective pain relief for individuals with low testosterone levels of any gender. In addition, our data endorse the interest of analgesic drugs inhibiting TRPA1 activity for the treatment or prevention of migraine and pain syndromes characterized by enhanced mechanosensitivity in males and females8,16,38, although careful modulation may be desirable since TRPA1 shows neuroprotective effects as a hypoxia sensor that drives vasodilatation and reduces ischemic damage16.

Methods

Animals

Adult male and female mice with a C57BL/6j background (Envigo, Horst, The Netherlands), wild-type or defective in Trpa117 or Trpm823 were bred in the animal facility at Universidad Miguel Hernández (UMH, Elche, Alicante, Spain). Experiments involving solely wild-type C57BL/6j mice or NTG knockout mice and their wild-type controls included 8–15-week-old age-matched mice, whereas experiments involving TRPM8 knockout and their respective wild-type controls included age-matched groups of 8–20-week-old mice. TRPM8 knockout mice were a gift from Dr. F. Viana (Instituto de Neurociencias de Alicante, Alicante, Spain). Care was taken to minimize the number of animals used and the stress they experienced. All experimental procedures were approved by the Animal Care and Use Committees of Universidad Miguel Hernández and the regional government (code: 2018/VSC/PEA/0250-3) and were conducted according to the ethical principles of the International Association for the Study of Pain for the evaluation of pain in conscious animals31, the European Parliament and the Council Directive (2010/63/EU) and the Spanish law (RD 53/2013). Housing conditions were maintained at 21 ± 1 °C and 55 ± 15% relative humidity in a controlled light/dark cycle (light on between 8:00 a.m. and 8:00 p.m.). Animals had free access to food and water except during manipulations and behavioral assessment. Experiments were performed blinded for NTG, genotype or pharmacological treatment depending on the studied condition.

Model of chronic migraine

Animals were exposed to a schedule of repeated NTG injections previously used to precipitate long lasting mechanical hypersensitivity2. Briefly, mice were injected with 10 mg/kg NTG or its vehicle every other day for 8 days (5 i.p. injections total). Two different NTG formulations were tested: first, 5 mg/1.5 ml ampoules and second, 50 mg/50 ml vials (Bioindustria Lim, Novi Ligure, Italy). The 5 mg/1.5 ml ampoules contained NTG dissolved on a vehicle made of 1 ml propylene glycol and 0.5 ml ethanol (Bioindustria Lim). Such solution was further dissolved in saline to obtain 1 mg/ml NTG, reaching final concentrations of 10% ethanol and 20% propylene glycol. This preparation was no longer used after the first behavioral experiment because the treatment with vehicle induced mechanical nociceptive sensitization by itself as shown in Supplementary Fig. 1. The second NTG formulation consisted of 50 mg/50 ml NTG vials containing a vehicle made of 5% dextrose and 0.105% propylene glycol in pure water (Bioindustria Lim). This NTG formulation or its vehicle was administered without further dilution. Such preparation was chosen to complete all the remaining experiments because the vehicle did not modify nociceptive sensitivity. Both the first and the second preparations were administered at 10 ml/kg intraperitoneally (i.p.), obtaining the same NTG dose of 10 mg/kg as described2.

Experimental design

Detailed description of the rationale, timing and experimental design followed in each experiment can be found in Supplementary Methods within the Supplementary Information file.

Assessment of mechanical sensitivity

Mechanical thresholds were quantified by measuring the hind paw withdrawal response to von Frey filament stimulation. To decrease stress, prior to baseline measurements mice were habituated for 4 h to the testing environment during 2 days. On the evaluation days, animals were also allowed to habituate for 1–2 h before testing in order to obtain appropriate behavioral immobility. Briefly, animals were placed in Plexiglas® chambers (10 × 10 × 14 cm) with a wire grid bottom through which the von Frey filaments (bending force range from 0.008 to 2 g) (PanLab, Cornellà, Barcelona, Spain) were applied, by using the up-down paradigm as described32. The filament of 0.4 g was first applied. Then, the strength of the next filament was decreased when the animal responded or increased when the animal did not respond. The upper limit value (2 g) was recorded as a positive response even if there was no withdrawal response, and the lower limit was recorded as negative even if there was withdrawal response (0.008). This up-down procedure was stopped 4 measures after the first change in animal responding (i.e., from response to no response or from no response to response). The sequence of the last 6 responses was used to calculate the mechanical threshold. Both ipsilateral and contralateral hind paws were alternatively tested whenever possible, and stimuli were applied at a minimum of 2 min intervals to avoid hypervigilance or sensitization between successive filament applications. Filaments were completely bent before considering responses and hold up to 4–5 s to consider a negative response. Clear paw withdrawal, shaking or licking were considered as nociceptive-like responses. The responses of both hind paws were averaged to obtain the mechanical threshold of each individual.

RNA extraction and RT-PCR

Trigeminal ganglia were isolated and frozen on dry ice until RNA extraction. Tissue was homogenized on ice using a polytron (Polytron PT 2000 Kinematica AG, Malters, Switzerland) and RNA was extracted with a TRIZOL (15596-026 Thermo Fisher Scientific) extraction method as described29. Briefly, chloroform was added to yield 2 phases, including one hydrophilic phase at the top containing RNA. Then after centrifugation at 12,000 × g, 10 min at 4 °C the aqueous phase was mixed with isopropanol to precipitate RNA. The resulting pellet was washed with ethanol and air-dried. RNA purity and quantity were assessed by spectrophotometry (NanoDrop 2000, Thermo Fisher Scientific). Retrotranscription to cDNA was conducted with First Strand Synthesis Kit (K1612, Thermo Fisher Scientific) using dT primers. Primers for cDNA amplification were: TRPA1 fw 5′-CCAGGTGG AACCTCATACCAA and rv 5′-CATTTCGTTAAGTACCAGACTGG, TRPM8 fw 5′-CTTCTCTAAGCATGATGGAC and rv 5′-GGTTTCTTCTCC TAAATGATAAG, GAPDH fw 5′-CCAAATGCTCCGTGGCTGACTGCT and rv 5′-GGTTAAGTCGAGGACAAAC. Relative expression values were obtained by applying the equation 2−ΔΔCT gene of interest/ΔΔCT GAPDH.

Mouse trigeminal primary cultures

Adult mice (8–14 weeks) were sacrificed by cervical dislocation and trigeminal ganglia were extracted, micro-dissected from nerve projections and kept in ice-cold HBSS solution. Trigeminal ganglia were incubated in collagenase 48 µg/ml, 3.5 U/ml (C7657, Merck) and dispase 3 mg/ml, 1.79 U/ml (17035-041, Thermo Fisher Scientific, Wal- tham, USA) for 45 min at 37 °C in 5% CO237. Thereafter, samples were mechanically disaggregated by pipetting 15 times through a 1 ml blue plastic tip. Neurons were separated from other cell types and tissue debris by placing the tissue homogenate over a 15% BSA solution (073K7601, Merck) and centrifuged 7 min at 300 × g. Then, cells were
seeded in 5 μl drops over crystals treated with 8.3 μg/ml poly-L-lysine (P9155, Merck) and 5 μg/ml laminin (L2020, Merck). In total, 30 min after seeding cultures were supplemented with 500 μl of culture medium and incubated for 12–16 h at 37 °C and 5% CO2. Cells were kept in a hormone-free culture medium consisting of Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) without Phenol Red (1139021, Thermo Fisher Scientific) IX Minimum Essential Medium (MEM) vitamin solution (1120052, Thermo Fisher Scientific), 1% penicillin/streptomycin (15140-022, Thermo Fisher Scientific) and home-made μg/ml N2-containing insulin (I2643, Merck), 0.1 mM putrescine hydrochloride (P7505, Merck), 3 mM sodium selenite (S5261 Merck), 100 μg/ml transferrin (T2872, Molecular Probes, Eugene, USA), 25 ng/ml NGF (S5141, Promega, Madison, USA) and 25 ng/ml hCDNF (450-10, Peprotech, London, UK).

**Fluorescence Ca2+ imaging**

Non-ratiometric calcium imaging experiments were conducted with the fluorescent indicator Fluo4-AM (F14201, Thermo Fisher Scientific). Trigeminal neurons or Human Embryonic Kidney 293 (HEK293) cells (CRL-1573 ATCC) were incubated with 5 mM (6 mg/ml) Fluo4-AM and 0.2% w/v pluronic acid (F-127, Thermo Fisher Scientific) for 60 min at 37 °C in standard extracellular solution (in mM: 140 NaCl, 3 KCl, 2.4 CaCl2, 1.3 MgCl2, 10 HEPES, and 5 glucose, adjusted to pH 7.4 with 1 M NaOH). Afterwards, cells were washed with standard extracellular solution for at least 20 min. Fluorescence measurements were obtained on an inverted microscope (Axiovert 200/B, ZEISS) coupled with a Hamamatsu FLASH 4.0 LT camera (C11440-42U30, Hamamatsu, Sunayama-cho, Japan). Before starting the experiment, an image of the microscopic field was obtained with transmitted light to create the regions of interest around cells with neuronal morphology. Then, Fluo4 was excited at 480 nm (excitation time 200 ms) with a rapid gating shutter (lambda-shutter 10/2 Sutter instruments, Novato, USA). Mean fluorescence intensity was recorded for each cell with HCImage DIA software (Hamamatsu Photonics) every 3 s. Calcium imaging recordings were performed at 35 °C. Response sizes after agonists were calculated by measuring peak minus basal values and divided by the positive control of the experiment, i.e., 40 mM KCl in trigeminal primary cultures, and 10 μM ionomycin in HEK293 and IMR90 human cell cultures. Responses were scored as positive if the increase in fluorescence was >0.2 arbitrary units. Substances dissolved in extracellular solution were delivered through a high-flow rate perfusion system controlled with an automatic system of valve clamps (PC-16 Bioscience Tools, S. Diego, USA). Cells were washed with extracellular solution between calcium responses for a period of at least 16 h at 37 °C in culture medium and kept at 37 °C and 5% CO2.

**Drugs tested in behavioral studies**

The TRPMS selective blocker AMTB hydrochloride (AMTB, N-(3-aminopropyl)-2-[[(3-methylphenyl) methyl]oxy]-N-(2-thienylmethyl) benzamide hydrochloride, Tocris, Bristol, UK) was dissolved in dimethyl sulfoxide (DMSO, Merck, Darmstadt, Germany) and was further diluted in saline to reach 2.5% DMSO. The range of AMTB doses (5–15 mg/kg, i.p., 10 ml/kg) was chosen based on dose conversion from previous experiments demonstrating efficacy in attenuating hyperactive bladder activity in rats. Mechanical sensitivity was measured 30 min after AMTB, based in previous behavioral results in mice.

The potent and selective TRPMS agonist WS12 ([IT,2S,5R]-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexanecarboxamide, Tocris) was dissolved in DMSO and diluted in corn oil to reach 2.5% DMSO. The range of WS12 i.p. doses (5–15 mg/kg, i.p., 10 ml/kg) was chosen based on previous data showing antinociceptive effects of WS12 in mice. WS12 was administered 30 min prior assessment of mechanical sensitivity. In the formalin test, WS12 was dissolved in DMSO and diluted in saline up to 0.6% DMSO to achieve an amount of 6 nmol in 20 μl as described. We used WS12 and not menthol or icilin as a TRPMS agonist to avoid unspecific signaling over TRPA1.

Testosterone (T1500, Merck) was dissolved in 45% 2-Hydroxypropyl-β-cyclodextrin in water to obtain a solution of 22 mg/ml for sustained delivery. This solution or its vehicle was introduced inside Alzet osmotic minipumps (Model 2004, Directeret, Cupertino, CA, USA) to achieve a testosterone delivery of 6 μg/h, based on previous studies obtaining significant effects in orchidectomized mice. In the experiments assessing the acute effect of testosterone in females, testosterone was dissolved in DMSO and diluted in corn oil to reach 2.5% DMSO as with WS12, and it was administered at 1 mg/kg, 1 h before the assessment of mechanosensitivity based on previous data assessing its effects on anxiety-like behavior.

**Drugs for cellular studies**

Fluoro-AM (F14201, Molecular Probes) was dissolved in DMSO at a concentration of 2 μg/ml used on HBSS at a concentration of 6 μg/ml to load the cells for calcium experiments. In calcium experiments, cells were under a constant flow of a standard extracellular solution (in mM: 140 NaCl, 3 KCl, 2.4 CaCl2, 1.3 MgCl2, 10 HEPES, and 5 glucose, adjusted to pH 7.4 with 1 M NaOH). Afterwards, cells were washed with standard extracellular solution for at least 20 min. Fluorescence measurements were obtained on an inverted microscope (Axiovert 200/B, ZEISS) coupled with a Hamamatsu FLASH 4.0 LT camera (C11440-42U30, Hamamatsu, Sunayama-cho, Japan). Before starting the experiment, an image of the microscopic field was obtained with transmitted light to create the regions of interest around cells with neuronal morphology. Then, Fluo4 was excited at 480 nm (excitation time 200 ms) with a rapid gating shutter (lambda-shutter 10/2 Sutter instruments, Novato, USA). Mean fluorescence intensity was recorded for each cell with HCImage DIA software (Hamamatsu Photonics) every 3 s. Calcium imaging recordings were performed at 35 °C. Response sizes after agonists were calculated by measuring peak minus basal values and divided by the positive control of the experiment, i.e., 40 mM KCl in trigeminal primary cultures, and 10 μM ionomycin in HEK293 and IMR90 human cell cultures. Responses were scored as positive if the increase in fluorescence was >0.2 arbitrary units. Substances dissolved in extracellular solution were delivered through a high-flow rate perfusion system controlled with an automatic system of valve clamps (PC-16 Bioscience Tools, S. Diego, USA). Cells were washed with extracellular solution between calcium responses for a period of at least 300 s to ensure recovery of basal fluorescence levels. Example dataset of calcium imaging (Fig. 2c, d) and the analysis instructions have been deposited in Github: https://github.com/greferball/Ca_Imaging_NatComm_2022.git.

**CGRP release assay**

Trigeminal cultures were incubated for 48 h, then cells were treated with the exocytosis inhibitor 10 μM DDO4107 (BCP Peptides SA, Spain) dissolved in water was used. After 4 h, cells were fixed with 4% paraformaldehyde (158127, Merck) for 20 min at room temperature. Immunocytochemistry

In total, 30 min after NTG exposure (vehicle 5% dextrose and 0.105% propylene glycol), the media was removed from the cells and the culture was washed with IX PBS (DB662, Merck) 3 times. Afterwards, cells were fixed with 4% paraformaldehyde (158127, Merck) for 20 min at room temperature. Permeabilization was achieved with 0.1% v/v Triton 100X (P8787, Merck) for 5 min and blocking with 5% Normal Goat Serum (NGS, G9023, Merck) for 1 h, both in IX PBS. Nuclei were labeled with primary antibodies rabbit anti-MAP (W203408, Merck) dissolved in 0.001% DMSO, 500 nM WS12 (3040/30, Tocris) dissolved in 0.01% DMSO, 10 μM testosterone dissolved in 0.01% DMSO, 10 μM ionomycin (I9657, Merck). NTG at 10 μM (Bioindustria LIM) was used in calcium imaging and in the CGRP release assay in the formulation containing 5% dextrose and 0.105% propylene glycol as vehicle. In the CGRP release experiment, 10 μM DDO4107 (BCP Peptides SA, San Quintin de Mediona, Spain) dissolved in water was used.
Culture and transfection of human cell lines

Human embryonic kidney 293 cells (HEK293) were maintained in DMEM plus Glutamax, supplemented with 10% Fetal Bovine Serum (FBS, Thermo Fisher Scientific) and 1% penicillin/streptomycin, and incubated at 37 °C in 5% CO2 atmosphere. For the study of TRPA1 function, HEK293 cells were plated in 24-well dishes at 2 × 105 cells/well and transiently transfected with human TRPA1 in a pCMV6-AC-GFP vector (Victoriate Vlachova, Czech Academy of Sciences) using Lipofectamine 3000 (Thermo Fisher Scientific). For the transfection, 2 ml of Lipofectamine 3000 was mixed with the DNA in DMEM plus Glutamax with 1% FBS. IMR90 fibroblast-like cells (CCL-186 ATCC, Virginia, USA) were seeded in 12 mm coverslips at 50,000 cells/well and were maintained in MEM enriched with 10% FBS and 1% penicillin/streptomycin at 37 °C in 5% CO2 atmosphere. For the initial experiments assessing TRPM8 function, HEK293 cells constitutively expressing human or rat TRPM8 were obtained from Prof. Belmonte Laboratory (Instituto de Neurociencias, San Juan, Alicante, Spain). All calcium imaging and electrophysiological recordings took place when cells reached 60% of confluence and 72 h after transfection when applicable.

Chemically-induced nocifensive behavior (formalin test)

Mice were individually placed into transparent chambers and were habituated for 1 h before testing. To evaluate the pain-relieving effect of WS12 against formalin-induced nocifensive behavior, 20 μl of a 45% 2-Hydroxypropyl-β-cyclodextrin solution containing 5% formalin (F9775, Merck) and 0.6% DMSO with or without 6 nmol of WS12 were injected subcutaneously into the plantar aspect of the right hind paw (i.pl.) by using a Hamilton syringe (Hamilton Syringe Gastight™ series 1700). TTL end, Merck) coupled to a 30-gauge needle. The time spent expressing nocifensive behavior (licking or biting of injected paw) was quantified in 5 min intervals during 60 min as described. To assess the influence of endogenous TRPM8 activity on the extinction of nocifensive behavior, mice received first 20 μl of 5% formalin dissolved in saline in their right hind paw, and nocifensive behavior was quantified as above. After the initial 60 min when the nocifensive responses ceased, AMTB (10 mg/kg) or vehicle (2.5% DMSO in saline) were administered i.p. and behavioral quantification continued for 1 h.

Orchidectomy

Orchidectomy was adapted from a previous procedure changing to a single midline scrotal incision to minimize tissue injury. Briefly, mice were anesthetized with a mixture of i.p. ketamine (75 mg/kg; Imalgene, 100 mg/ml, Boehringer Ingelheim, Ingelheim/Rhein, Germany) and xylazine (15 mg/kg, Merck) and a single midline scrotal incision was made. The testes were exposed, and the vas deferens and testicular blood vessels were ligated with 2 tied knots of 6–0 black silk (8065195601, Alcon Cusi S.A., Barcelona, Spain). An incision was made between the 2 knots to remove testes and epididymis and the incision was closed with three additional square knots after ensuring hemostasis. Sham surgeries were performed similarly but the testicles were exposed and not ligated or removed. Subsequent nociceptive evaluations were conducted 3 weeks after surgeries.

Testosterone replacement treatment

Testosterone or its vehicle (45% 2-Hydroxypropyl)-β-cyclodextrin in water) were placed into Alzet osmotic minipumps (Model 2004, 0.23 μl/h for 28 days) following manufacturer instructions. Minipumps were implanted subcutaneously between the scapulae under ketamine (75 mg/kg)-xylazine (15 mg/kg) anaesthesia. The pump was set to deliver vehicle or testosterone at an estimated dose of 6 μg/h, based on previous studies obtaining significant effects in orchidectomized mice. Testing and NGT injections began after 5 days of minipump implantation.

Patch-clamp whole-cell recordings

Whole cell recordings were conducted using an EPC-10 amplifier with Patchmaster software (both from HEKA Electronic, Dr. Schulze GmbH, Germany). Patch pipettes, prepared from thin-wall borosilicate capillary glass tubing (Warner Instruments, Hamden, CT, USA) were pulled with a horizontal flaring/brown Micropipette puller Model P-97 from Sutter Instruments to a final resistance of 2–4 MΩ when filled with internal solution. Recordings were acquired at 10 kHz and low-pass filtered at 3 kHz. Recordings with leak currents >200 pA or series resistance >15 MΩ were discarded. Cells were seeded on 12 mm diameter glass coverslips treated with poly-L-lysine solution. Intracellular pipette solution contained in mM: 150 NaCl, 3 MgCl2, 5 EGTA and 10 HEPES, pH 7.2 with CsOH. Extracellular physiological solution contained in mM: 150 NaCl, 6 CsCl, 1 MgCl2, 1.5 CaCl2, 10 glucose and 10 HEPES, pH 7.4 with NaOH. All measurements were performed at room temperature. After seal opening, cells were maintained at a holding potential of −60 mV for few minutes and then a voltage ramp from −120 to +120 mV of 300 ms duration was applied.

Knockdown of androgen receptor in HEK 293 cells expressing human TRPM8

HEK293 cells expressing human TRPM8 were transfected with DMEM plus Glutamax with 1% FBS. IMR90 fibroblast-like cells (CCL-186 ATCC, Virginia, USA) were seeded in 12 mm coverslips at 50,000 cells/well and were maintained in MEM enriched with 10% FBS and 1% penicillin/streptomycin plus 1% Penicillin/Streptomycin (Gibco, 15140-044). Cells were seeded on 12 mm diameter glass coverslips treated with poly-L-lysine solution. Intracellular pipette solution contained in mM: 150 NaCl, 3 MgCl2, 5 EGTA and 10 HEPES, pH 7.2 with CsOH. Extracellular physiological solution contained in mM: 150 NaCl, 6 CsCl, 1 MgCl2, 1.5 CaCl2, 10 glucose and 10 HEPES, pH 7.4 with NaOH. All measurements were performed at room temperature. After seal opening, cells were maintained at a holding potential of −60 mV for few minutes and then a voltage ramp from −120 to +120 mV of 300 ms duration was applied.

Protein extraction and western blotting

Total protein from HEK 293 cells was extracted using lysis buffer (150 mM NaCl, 50 mM Tris-Base, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, pH 8) containing L100 Halt Protease Inhibitor Cocktail EDTA-free (87785, Thermo Scientific). After 40 min incubation with lysis buffer, solubilized proteins were collected by centrifugation at 9400 × g for 15 min. Protein concentration was determined with Pierce BCA Protein Assay Kit (23225, Thermo Scientific). In total, 20 μg of total protein were prepared in loading buffer (10X: 600 mM Tris-HCl, 400 mM DTT, 1% bromophenol blue, 20% SDS, 50% glycerol, pH 6.8) and heated to up to 95 °C for 5 min before loading the gel. Proteins were separated by SDS-PAGE in 7.5% gels. Electrophoresis ran in running buffer (0.3% Tris-Base, 1.44% glycine, 0.1% SDS, pH 8.4) at 100 V during the first 10 min, and then at 150 V until the end. Separated proteins were transferred onto a 0.45 μm nitrocellulose membrane (Bio-Rad) using a wet blotting system for 2 h at 100 V and 4 °C in transfer buffer (25 mM Tris-Base, 190 mM glycine, 0.1% SDS, 20% methanol, pH 8.4). Afterwards, the membrane was blocked with 5% BSA for 1 h. Androgen receptor (AR) and β-tubulin were probed with
specific primary antibodies anti-AR (1:100 in 1% BSA/TBST; sc-7305, Santa Cruz Biotechnology) and anti-β-tubulin (1:1000 in 2.5% BSA/TBST; 10094-1-AP, Proteintech) and were incubated overnight (16 h) at 4 °C. After six 5-min washes with TBST (20 mM Tris-Base, 150 mM NaCl, 0.1% Tween-20, pH 7.5) the membrane was incubated with secondary antibodies anti-mouse IgG-HRP (1:10,000 in 1% BSA/TBST; A4416, Sigma) or anti-rabbit IgG-HRP (1:25,000 in 2.5% BSA-TBST; A0545, Sigma) for 1 h at room temperature. After six 5-min washes with TBST, proteins were detected with substrate SuperSignal West Pico Plus (34577, Thermo Scientific). Chemiluminescence was visualized with ChemiDoc imaging system (Bio-Rad).

Statistical analyses

Time courses of nociceptive behavioral data conducted in male and female mice were analyzed using two-way repeated measures ANOVA with time as within-subjects factor and NTG treatment or genotype as between-subject factors. The time courses involving orchidectomized animals were analyzed with three-way repeated measures ANOVA, with time as within-subjects factor and either NTG and orchidectomy or genotype and testosterone as between-subject factors. Levene’s test of equality of error variances and Mauchly’s sphericity tests were used to assess normality of the data and Bonferroni post hoc pairwise comparisons were subsequently conducted when appropriate. Three-way ANOVA was also used to analyze the data of WS12 experiments (time point, WS12, NTG) whereas a within-design was chosen to analyze the effects of the AMTB doses in wild-type males recovered from sensitization (Friedman’s test followed by Benjamini adjustment). A three-way ANOVA was also used to analyze AMTB effects on NTG-exposed orchidectomized animals (Time point, Testosterone, Genotype). The time-course data of the chemically-induced nociceptive behavior was analyzed with repeated unadjusted t-tests to avoid assumptions of similar variances for the first and the second phases of the formalin test and posterior measurements. For the cellular studies, data normality was first assessed with D’Agostino–Pearson or Shapiro–Wilk test for the patch recordings. Then, comparisons of two groups were analyzed accordingly with t-tests or Mann–Whitney U tests, whereas comparisons of more than two groups were analyzed with either one-way ANOVA followed by Bonferroni or Kruskal–Wallis followed by Mann–Whitney U tests. RT-PCR and cellular data containing two factors were analyzed with two-way ANOVA followed by Bonferroni. Sample size for animal and cellular studies was estimated based on previous experience in our laboratories using similar behavioral and cellular approaches. Raw data can be found in the Source Data File and results of the statistical tests are included in the Supplementary Information file. Throughout the manuscript, data are expressed as mean ± SEM values and individual datapoints are shown whenever possible. Differences were considered statistically significant when p values were <0.05. Statistical analyses were performed using IBM SPSS 25 Software (IBM, Chicago, IL, USA), Microsoft Excel 2019 MSO (Redmond, WA, USA) and GraphPad Prism 7.04 (GraphPad Software Inc., San Diego, CA, USA). Additional distribution data can be found in the Supplementary Statistical Results subsection of the Supplementary Information file.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All source data from the figures are available within the manuscript as a Source data file and results of statistical analyses are provided within the Supplementary Information file. Example dataset of calcium imaging (Fig. 2c, d) and analysis instructions have been deposited in Github: https://github.com/greferball/Ca_Imaging_NatComm_2022.git. All the calcium imaging datasets generated and analyzed during the study are available from the corresponding authors on request. Data used for computational analyses are available as Supplementary Information in the zip folder Computational_les.zip which contains instructions in a readme.txt and scripts. Source data are provided with this paper.

References

1. Safiri, S. et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163, E293–E309 (2022).
2. Iannone, L. F., De Logu, F., Geppetti, P. & De Cesaris, F. The role of TRP ion channels in migraine and headache. Neurosci. Lett. 768, 136380 (2022).
3. Ferrari, M. D. et al. Migraine. Nat. Rev. Dis. Prim. 8, 2 (2022).
4. Demartini, C. et al. Nitroglycerin as a comparative experimental model of migraine pain: from animal to human and back. Prog. Neurobiol. 177, 15–32 (2019).
5. Marone, I. M. et al. TRPA1/NOX in the soma of trigeminal ganglion neurons mediates migraine-related pain of glyceryl trinitrate in mice. Brain 141, 2312–2328 (2018).
6. Pradhan, A. et al. Characterization of a novel model of chronic migraine. Pain 155, 269–274 (2014).
7. Louter, M. A. et al. Cutaneous allodynia as a predictor of migraine chronification. Brain 136, 3489–3496 (2013).
8. Han, S. M. et al. Prevalence and characteristics of cutaneous allodynia in probable migraine. Sci. Rep. 11, 2467 (2021).
9. Bigal, M. E. et al. Prevalence and characteristics of cutaneous allodynia in headache sufferers: a population study. Neurology 70, 1525–1533 (2008).
10. Scher, A. I. et al. Epidemiology of migraine in men: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Cephalalgia 39, 296–305 (2019).
11. Nassini, R. et al. The ‘headache tree’ via umbellulone and TRPA1 activates the trigeminovascular system. Brain 135, 376–390 (2012).
12. De Logu, F. et al. Schwann cells expressing nociceptive channel TRPA1 orchestrate ethanol-evoked neuropathic pain in mice. J. Clin. Invest. 129, 5424–5441 (2019).
13. Charles, A. & Pozo-Rosich, P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394, 1765–1774 (2019).
14. Ashina, M. et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397, 1505–1518 (2021).
15. Denner, A. C., Vogler, B., Messlinger, K. & De Col, R. Role of transient receptor potential ankyrin 1 receptors in rodent models of meningeal nociception—experiments in vitro. Eur. J. Pain. 21, 843–854 (2017).
16. Paige, C. et al. A female-specific role for calcitonin gene-related peptide (CGRP) in rodent pain models. J. Neurosci. 42, 1930–1944 (2022).
17. Chisman, D. L. et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat. Genet. 43, 695–698 (2011).
18. Ling, Y. H., Chen, S. P., Fann, C. S. J., Wang, S. J. & Wang, Y. F. TRPM8 genetic variant is associated with chronic migraine and allodynia. J. Headache Pain 20, 115 (2019).
19. Borhani-Haghighi, A. et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, cross-over study. Int. J. Clin. Pr. 64, 451–456 (2010).
20. St. Cyr, A. et al. Efficacy and tolerability of STOPAIN for a migraine attack. Front. Neurol. 6, 11 (2015).
21. Andersen, H. H., Gazerani, P. & Arendt-Nielsen, L. High-concentration L-menthol exhibits counter-irritancy to neurogenic inflammation, thermal and mechanical hyperalgesia caused by trans-cinnamaldehyde. J. Pain. 17, 919–929 (2016).
22. Peier, A. M. et al. A TRP channel that senses cold stimuli and menthol. Cell 108, 705–715 (2002).
23. Bautista, D. M. et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 448, 4–9 (2007).
24. Dhaka, A. et al. TRPM8 is required for cold sensation in mice. Neuron 54, 371–378 (2007).
25. Pérez De Vega, M. J., Gómez-Monterrey, I., Ferrer-Montiel, A. & González-Muñiz, R. Transient receptor potential melastatin 8 channel (TRPM8) modulation: cool entryway for treating pain and cancer. J. Med. Chem. 59, 10006–10029 (2016).
26. Liu, Y. et al. TRPM8 channels: a review of distribution and clinical role. Eur. J. Pharmacol. 882, 173312 (2020).
27. Ordás, P. et al. Expression of the cold thermoreceptor TRPM8 in rodent brain thermoregulatory circuits. J. Comp. Neurol. 529, 234–256 (2021).
28. Asutikh, S. et al. The TRPM8 protein is a testostereone receptor: II. Functional evidence for an ionotropic effect of testosteron on TRPM8. J. Biol. Chem. 290, 2670–2688 (2015).
29. Lesnak, J. B., Inoue, S., Lima, L., Rasmussen, L. & Sluka, K. A. Testostereone protects against the development of widespread muscle pain in mice. Pain 161, 2898–2908 (2020).
30. Rosen, S., Ham, B. & Mogil, J. Sex differences in neuroimmunity and pain. J. Neurosci. Res. 95, 500–508 (2017).
31. Shields, L. B., Seifert, T., Shelton, B. J. & Plato, B. M. Testosterone levels in men with chronic migraine. Neurof. Int 11, 8079 (2019).
32. Camprubi-Robles, M., Planells-Cases, R., Ferrer-Montiel, A. & Robles, C. Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors. FASEB J. 23, 3722–3733 (2009).
33. Liu, B. et al. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain 154, 2169–2177 (2015).
34. McNamara, C. R. et al. TRPA1 mediates formalin-induced pain. Proc. Natl Acad. Sci. USA 104, 13525–13530 (2007).
35. Journigan, V. B. et al. Structural and in vitro functional characterization of a menthy TRPM8 antagonist indicates species-dependent regulation. ACS Med. Chem. Lett. 12, 758–767 (2021).
36. Diver, M. M., Cheng, Y. & Julius, D. Structural insights into TRPM8 inhibition and desensitization. Science 365, 1434–1440 (2019).
37. Fenton, L. E., Macedo, C. G., Torres-Chávez, K. E., Fischer, L. & Tambelli, C. H. Activational action of testosterone on androgen receptors protects males preventing tempomandibular joint pain. Pharm. Biochem. Behav. 152, 30–35 (2017).
38. Ji, Y., Hu, B., Li, J. & Traub, R. J. Opposing roles of estradiol and testostereone on stress-induced visceral hypersensitivity in rats. J. Pain. 19, 764–776 (2018).
39. Watanabe, M. et al. Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. Brain https://doi.org/10.1093/brain/awac104 (2022).
40. Demartini, C. et al. The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. J. Headache Pain. 18, 94 (2017).
41. Liu, C. et al. A non-covalent ligand reveals biased agonism of the TRPA1 ion channel. Neuron 109, 273–284 (2021).
42. Martínez-Rojas, V. A. et al. Peripheral and spinal TRPA1 channels contribute to formalin-induced long-lasting mechanical hypersensitivety. J. Pain. Res. 11, 51–60 (2018).
43. Liu, B. Y. et al. Menthol suppresses laryngeal C-fiber hypersensitivity to cigarette smoke in a rat model of gastroesophageal reflux disease: the role of TRPM8. J. Appl. Physiol. 118, 635–645 (2015).
44. Kayama, Y. et al. Functional interactions between transient receptor potential M8 and transient receptor potential V1 in the trigeminal system: relevance to migraine pathophysiology. Cephalalgia 38, 833–845 (2018).
45. Ren, L., Dhaka, A. & Cao, Y. Q. Function and postnatal changes of dorsal afferent fibers expressing TRPM8 channels. Mol. Pain. 11, 37 (2015).
46. Proudfoot, C. J. et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr. Biol. 16, 1591–1605 (2006).
47. Knowlton, W. et al. A sensory-labeled line for cold. TRPM8-expressing sensory neurons define the cellular basis for cold, cold pain, and cooling-mediated analgesia. J. Neurosci. 33, 2837–2848 (2013).
48. Patel, R. et al. Anti-hyperalgesic effects of a novel TRPM8 agonist in neuropathic rats: a comparison with topical menthol. Pain 155, 2097–2107 (2014).
49. Eccles, R. Menthol and related cooling compounds. J. Pharm. Pharmacol. 46, 618–630 (1994).
50. Wei, C., Kim, B. & McKemy, D. D. Transient receptor potential melastatin 8 (TRPM8) is required for nitroglycerin and calcitonin gene-related peptide induced migraine-like pain behaviors in mice. Pain https://doi.org/10.1097/j.pain.0000000000002635 (2022).
51. Burgos-Vega, C. et al. Meningeal transient receptor potential channel M8 activation causes cutaneous脸和 hindpaw alloodynia in a preclinical rodent model of headache. Cephalalgia 36, 185–193 (2016).
52. Yin, Y. et al. Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel. Science 363, 9334 (2019).
53. Reichling, D. B. & Levine, J. D. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 32, 611–618 (2009).
54. Corder, G. et al. Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science 341, 1394–1399 (2013).
55. Cabañero, D., Campillo, A., Célérier, E., Romero, A. & Puig, M. M. Pronociceptive effects of remifentanil in a mouse model of postsurgical pain: effect of a second surgery. Control 111, 1334–1345 (2009).
56. Shapovalov, G. et al. Opiates modulate thermosensation by internalizing cold receptor TRPM8. Cell Rep. 4, 504–515 (2019).
57. Carvalho, A. L. et al. TRPM8 modulates temperature regulation in a sex-dependent manner without affecting cold-induced bone loss. PLoS ONE 16, e0231060 (2021).
58. Khosla, S. & Monroe, D. G. Regulation of bone metabolism by sex steroids. Cold Spring Harb. Perspect. Med. 8, a031211 (2018).
59. Frye, C. A., Koonce, C. J., Edinger, K. L., Osborne, D. M. & Walf, A. A. Androgens with activity at estrogen receptor beta have anxiolytic and cognitive-enhancing effects in male rats and mice. Horm. Behav. 54, 726–734 (2008).
60. White, H. D. & Robinson, T. D. A novel use for testosterone to treat central sensitization of chronic pain in fibromyalgia patients. Int. Immunopharmacol. 27, 244–248 (2015).
61. Bartley, E. J. et al. Natural variation in testosterone is associated with hypoalgesia in healthy women. Clin. J. Pain. 31, 730–739 (2015).
62. Yoo, H. S. & Napoli, J. L. Quantification of dehydroepiandrosterone, 17β-estradiol, testosterone, and their sulfates in mouse tissues by LC-MS/MS. Anal. Chem. 91, 14624–14630 (2019).
63. Mohandass, A. et al. TRPM8 as the rapid testosterone signaling receptor: implications in the regulation of dimorphic sexual and social behaviors. FASEB J. 34, 10887–10906 (2020).
64. Nersesyan, Y. et al. Oxytocin modulates nociception as an agonist of pain-sensing TRPV1. Cell Rep. 21, 1681–1691 (2017).
65. Gkika, D. et al. Testosterone-androgen receptor: the steroid link inhibiting TRPM8-mediated cold sensitivity. FASEB J. 34, 7483–7499 (2020).
66. Bidaux, G. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. Endocr. Relat. Cancer 12, 367–382 (2005).

67. Yin, Y. et al. Structure of the cold- and menthol-sensing ion channel TRPM8. Science 359, 237–241 (2018).

68. Paricio-Montesinos, R. et al. The sensory coding of warm perception. Neuron 106, 830–841.e4 (2020).

69. Majeed, Y. et al. Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone. Cell Calcium 51, 1–11 (2012).

70. Giorgi, S., Nikolaeva-Koleva, M., Alarcón-Alarcón, D., Butrón, L. & González-Rodríguez, S. Is TRPA1 burning down TRPV1 as druggable target for the treatment of chronic pain. Int. J. Mol. Sci. 20, 2906 (2019).

71. Ferrer-Montiel, A. et al. Advances in modulating thermosensory TRP channels. Expert Opin. Ther. Pat. 22, 999–1017 (2012).

72. Pires, P. W. & Earley, S. Neuronal genetic mouse models for TRP channels in the cerebral endothelium following ischemic stroke. Elife 7, e35316 (2018).

73. Kwan, K. Y. et al. TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 50, 277–289 (2006).

74. Zimmermann, M. Ethical considerations in relation to pain in animal experimentation. Acta Physiol. Scand. Suppl. 554, 221–233 (1986).

75. Chaplan, S. R. et al. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–63 (1994).

76. Chomzyński, P. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal. Biochem. 162, 156–159 (1987).

77. Ponsati, B. et al. An inhibitor of neuronal exocytosis (DDO4107) displays long-lasting in vivo activity against chronic inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 341, 634–645 (2012).

78. Jocher, G., Mannschatz, S. H., Offterdinger, M. & Schweigreiter, R. Microfluorics of small-population neurons allows for a precise quantification of the peripheral axonal growth state. Front. Cell. Neurosci. 12, 166 (2018).

79. Devesa, I. et al. cGORP is essential for algesic exocytotic mobilization of TRPV1 channels in peptidergic nociceptors. Proc. Natl Acad. Sci. USA 111, 18345–18350 (2014).

80. Nair, A. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27–31 (2016).

81. Lashinger, E. S. R. et al. AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am. J. Physiol. Renal Physiol. 295, F803–10 (2008).

82. Willis, D. N., Liu, B., Ha, M. A., Jordt, S. & Morris, J. B. Menthol attenuates respiratory irritation responses to multiple cigarette smoke irritants. FASEB J. 25, 4434–4444 (2011).

83. Karashima, Y. et al. Bimodal action of menthol on the transient receptor potential channel TRPA1. J. Neurosci. 27, 9874–9884 (2007).

84. Donner, D. G. et al. Trenbolone improves cardiometabolic risk factors and myocardial tolerance to ischemia-reperfusion in male rats with testosterone-deficient metabolic syndrome. Endocrinology 157, 368–381 (2016).

85. Zhao, R. et al. A GPR174–CCL21 module imparts sexual dimorphism to humoral immunity. Nature 577, 416–420 (2020).

86. Frye, C. A., Edinger, K. & Sumida, K. Androgen administration to aged male mice increases anti-anxiety behavior and enhances cognitive performance. Neuropsychopharmacology 33, 1049–1061 (2008).

87. Nikolaeva-Koleva, M. et al. A capsaicinoid-based soft drug, AG1529, for attenuating TRPV1-mediated histaminergic and inflammatory sensory neuron excitability. Sci. Rep. 11, 246 (2021).

88. Tonello, R. et al. The peptide Phot1B, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice. Br. J. Pharm. 174, 57–69 (2017).

89. Sophocleous, A. & Idris, A. I. Ovariectomy/orchiectomy in rodents. Methods Mol. Biol. 1914, 261–267 (2019).

90. Cabañero, D. et al. Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain. Elife 9, 1–24 (2020).

Acknowledgements
We are thankful to the following funding bodies: grants from MICYT/AEI no. SAF2015-66275-C21-R and RTI2018-097189-B-C21 (DOI /10.13039/501100011033), ERDF A way of making Europe, by the “European Union” to A.F.M. and A.F.C., and fellowship grants BES-2016-077985 to D.A.A. and PRE2019-091317 to J.d.A.L.; grants form GVA, PROMETEO/2021/031 to A.F.M. and A.F.C.; UMH-PAR2019 to A.F.C. and A.F.M.; GVA fellowship grant GRISOLIAP/2019/09444/19 to S.G. Authors thank Gema Osuna Tenorio, Laura Butró and José Manuel Serrano García for their help and technical expertise. We thank Dr. F. Viana for providing the TRPM8 knockout mice.

Author contributions
D.A.A. conducted calcium imaging, cell culture, immunofluorescence, RT-PCR experiments, performed formalin behavioral assays, designed experiments, analyzed the data, wrote and edited the first and subsequent drafts of the manuscript. D.C. conducted all behavioral assays, performed surgeries, analyzed the data, conceptualized and designed experiments, coordinated in vivo, in vitro and computerized experiments and wrote and edited the first and subsequent drafts of the manuscript. J.d.A.L. executed and analyzed docking experiments, conducted protein extraction, western blotting and cell cultures and wrote the first and subsequent drafts of the manuscript. M.N.K. conducted the electrophysiological assays and wrote manuscript. S.G. conducted knockdown experiments and wrote manuscript. G.F.B. supervised and executed docking experiments and revised and edited the manuscript. A.F.M. supervised and designed experiments, conceptualized the project, revised and edited the manuscript and provided funding. A.F.M. supervised and designed experiments, conceptualized the project, wrote, revised and edited the manuscript and provided funding.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-33835-3.

Correspondence and requests for materials should be addressed to David Cabañero, Asia Fernández-Carvajal or Antonio Ferrer-Montiel.

Peer review information Nature Communications thanks Cristina Tasorelli and the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permissions information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
